VaDrugDiscoveryRx was a resounding success with 146 attendees from academia, the private sector and government. The meeting showcased the dynamic drug discovery environment in the state of Virginia and focused on the development of public-private drug discovery partnerships, which are foundational to translational research.

Symposium Program

The Symposium Program, which contains the Abstracts for all these presentations is now available.
This Symposium could not have taken place without the generous support of our Institutional Sponsors, for which we express our sincere gratitude!

Gold Sponsors

  • The INOVA Schar Cancer Institute
  • Johnson & Johnson Innovations

Silver Sponsors

  • Prince William County Economic Development Board

Bronze Sponsors

  • Advion
  • AMRI
  • Biotage
  • Collaborative Drug Discovery
  • Hamilton
  • Key Organics
  • MilliporeSigma
  • Sciex
  • University of Virginia Licensing and Venture Group


  • KeViRx
Keynote speakers

Michael Weingarten

Director, SBIR Development Center, National Cancer Institute, Rockville, MD 20850

Talk: “NCI’s multi-faceted Support for Early Stage Biotechnology Innovation”

Daniel V. Paone

Discovery Partnerships with Academia, GlaxoSmithKline, Collegeville, PA 19486

Talk: “Characteristics of successful academic-pharma partnerships”

Jeffrey Gallagher

CEO, Virginia Bio, 800 Leigh St., Richmond, VA 23219

Talk: “An overview of biotech/pharma businesses in VA”

Bruce Littlefield

Distinguished Scientist and Head, Translational Medicine in the Global Oncology group at Eisai, a global pharmaceutical company headquartered in Tokyo.

Talk: “Justify-ing a perfect (drug development) trifecta”

Founders Hall, George Mason University